TY - JOUR
T1 - SOHO State of the Art Update and Next Questions
T2 - IDH Therapeutic Targeting in AML
AU - DiNardo, Courtney D.
AU - Stein, Eytan M.
N1 - Funding Information:
Eytan M. Stein has served on advisory boards for Celgene, Agios, Pfizer, Novartis, Syros, Daiichi-Sankyo, Bayer, and Astellas. He has received research support from Celgene, Agios, Syros and Bayer. Courtney D. DiNardo has served in an advisory role and received honoraria from Abbvie, Agios, Celgene, Karyopharm, Medimmune, and Syros.
Publisher Copyright:
© 2018 Elsevier Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used.
AB - Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used.
KW - Acute myeloid leukemia
KW - Beta-hydroxyglutarate
KW - Enasidenib
KW - Isocitrate dehydrogenase
KW - Ivosidenib
UR - http://www.scopus.com/inward/record.url?scp=85056149709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056149709&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.10.007
DO - 10.1016/j.clml.2018.10.007
M3 - Review article
C2 - 30416011
AN - SCOPUS:85056149709
SN - 2152-2650
VL - 18
SP - 769
EP - 772
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 12
ER -